Opioid-Sparing Effect of Oral Cannabinoids

• Status: Not yet recruiting
• Trial end date: 2023-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The investigators are conducting a pilot (i.e. a small study) in order to find out the effectiveness and safety of medical cannabis in the management of chronic pain. At the end of this 3 month study, investigators will gather information on how easy it is for patients to enroll and complete the entire study. The results of this pilot study will then be used to determine if the weaning protocol is useful and help the study team design a larger randomized controlled trial.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Health Network, Toronto

Criteria

Inclusion Criteria:

1. Age ≥ 25 years

2. Able to understand and read English

3. Experiencing chronic, non-palliative pain

4. Current daily opioid consumption ≥ 50 mg MEQ

Exclusion Criteria:

1. Using nabilone, nabiximols or cannabis weekly for ≥ 12 weeks in the past year

2. Known allergy to cannabis or any cannabinoid

3. Diagnosed with a serious lung, liver, kidney or heart disease

4. Have a personal or family history of serious mental disorders such as schizophrenia, psychosis, depression, or bipolar disorder

5. Currently pregnant or breast-feeding (a negative urine pregnancy test must be obtained for women of child bearing potential during pretreatment evaluation)

6. Men and women planning to start a family in the next 12 weeks

7. Has declared a current alcohol or substance use disorder (excluding opioid use disorder)